Genfit S.A. (GNFT) - Total Liabilities
Based on the latest financial reports, Genfit S.A. (GNFT) has total liabilities worth $164.21 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Genfit S.A. to track the company's year-over-year net asset growth rate.
Genfit S.A. - Total Liabilities Trend (2004–2024)
This chart illustrates how Genfit S.A.'s total liabilities have evolved over time, based on quarterly financial data. See GNFT free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Genfit S.A. Competitors by Total Liabilities
The table below lists competitors of Genfit S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanning Sugar Industry Co Ltd
SHE:000911
|
China | CN¥4.80 Billion |
|
Apollo Pipes Limited
NSE:APOLLOPIPE
|
India | Rs2.91 Billion |
|
Hitit Bilgisayar Hizmetleri AS
IS:HTTBT
|
Turkey | TL655.34 Million |
|
Mastersystem Infotama Tbk.
JK:MSTI
|
Indonesia | Rp1.01 Trillion |
|
Blackrock Silver Corp
V:BRC
|
Canada | CA$2.27 Million |
|
Taisun Enterprise Co Ltd
TW:1218
|
Taiwan | NT$2.44 Billion |
|
Sino AG
F:XTP
|
Germany | €2.38 Million |
|
Shattuck Labs Inc
NASDAQ:STTK
|
USA | $7.09 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Genfit S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GNFT market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genfit S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genfit S.A. (2004–2024)
The table below shows the annual total liabilities of Genfit S.A. from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.20 Million | -22.39% |
| 2023-12-31 | $105.92 Million | -12.47% |
| 2022-12-31 | $121.01 Million | -25.59% |
| 2021-12-31 | $162.62 Million | -24.28% |
| 2020-12-31 | $214.78 Million | -4.88% |
| 2019-12-31 | $225.79 Million | +8.27% |
| 2018-12-31 | $208.54 Million | +10.36% |
| 2017-12-31 | $188.95 Million | +706.91% |
| 2016-12-31 | $23.42 Million | +69.17% |
| 2015-12-31 | $13.84 Million | -13.15% |
| 2014-12-31 | $15.94 Million | +5.84% |
| 2013-12-31 | $15.06 Million | -10.09% |
| 2012-12-31 | $16.75 Million | -31.97% |
| 2011-12-31 | $24.62 Million | +7.05% |
| 2010-12-31 | $23.00 Million | +0.39% |
| 2009-12-31 | $22.91 Million | -2.98% |
| 2008-12-31 | $23.61 Million | +59.04% |
| 2007-12-31 | $14.85 Million | -19.64% |
| 2006-12-31 | $18.47 Million | +5.88% |
| 2005-12-31 | $17.45 Million | +5.06% |
| 2004-12-31 | $16.61 Million | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more